The outlook for many patients with epithelial ovarian cancer remains poor despite apparent advances in surgery and chemotherapy over the past few decades.
The outlook for many patients with epithelial ovarian cancer remains poor despite apparent advances in surgery and chemotherapy over the past few decades. The Third Birmingham Gynaecological Cancer Workshop was convened to address specific problems in the management of ovarian cancer and to determine whether new approaches could be adopted.
In an attempt to take a different view of ovarian cancer, speakers from the field presented data which were then challenged by oncological experts from other fields of cancer, Professor Giles from the University of Leeds and Dr Thatcher from the Christie Hospital in Manchester. Over the day discussions were wide ranging but concentrated on several main issues. 
Chemotherapy
The discussion of chemotherapy was introduced by Dr Wiltshaw. In a review of patients treated at the Royal Marsden Hospital over nearly 20 years she demonstrated that the introduction of cisplatin into treatment protocols had had a major impact on survival and this had been one major factor influencing outcome in patients with advanced disease (FIGO stages III and IV). It remained the case, however, that despite dose intensification and the use of combination therapy, extension of life with effective chemotherapy remained the norm and ultimate cure was unlikely in this group of patients. Further dose intensification using high dose carboplatin did appear to be improving the outlook for patients with stage IV disease in whom the prognosis was particularly poor, and a randomised trial is underway in earlier stage disease to see if cures might result.
Toxicity of chemotherapy
The toxicity of drugs such as the platinum compounds remained a major problem. Neurotoxicity is one of the major dose limiting effects of cisplatin and can be seen with carboplatin, especially when used in combination with cisplatin. Dr Neijt (Utrecht, Netherlands) reported on the development of a neuropeptide ORG2766 which appears to protect against the problems of neurotoxicity. In a randomised study carried out by the Netherlands Ovarian Cancer Group neurotoxicity had been almost completely eliminated when four courses of cisplatin based chemotherapy were administered concurrently with this compound and had a major protective effect when more than four courses were given.
Professor Pecorelli discussed the possibility of dose intensification using weekly cisplatin therapy. A large pilot study was currently being carried out by the Northern Italian Group but randomised trials are required to determine whether this approach offers potentially significant benefits in terms of improved response rate, remission duration and quality of life. of therapy are being subjected to close scrutiny. In particular the question of curability of any ovarian cancer is a major issue since this will affect the management of both early and late stage disease and will also determine the sort of trials which should be carried out for adjuvant treatment. Equally the role of intensive surgical staging and supraradical surgery is being questioned at the present time. While chemotherapy has a palliative role to play, its precise role in tumour control, achieving a reasonable quality of life for patients with advanced disease and significantly extending remission duration are all under investigation. The use of prognostic indices may help to identify patients who would most benefit from the various chemotherapy regimens.
